Scancell Holdings' () Dr Cliff Holloway talks to Proactive London's Katie Pilbeam after being awarded funds from Innovate UK to produce a COVID-19 vaccine.
Holloway explains how the company is using their immunotherapies knowledge which is used in their cancer research projects to help with the COVID-19 drive.
Alongside this the company's lead drug, SCIB-1 to treat skin cancer has recently entered a phase II clinical trial in the UK.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE